Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs Indian Medical PG Practice Questions and MCQs

Question 431: Considering the therapies for myasthenia gravis, which one of the following adverse effects can be caused by neostigmine and pyridostigmine?

A. Bronchodilation
B. Diarrhea (Correct Answer)
C. Cycloplegia
D. Irreversible inhibition of acetylcholinesterase

Explanation: **Explanation:** **Neostigmine** and **Pyridostigmine** are quaternary ammonium compounds that act as reversible acetylcholinesterase (AChE) inhibitors. By inhibiting the enzyme responsible for breaking down acetylcholine (ACh), they increase the concentration of ACh at both nicotinic and muscarinic receptors. **Why Diarrhea is Correct:** The gastrointestinal tract is rich in muscarinic ($M_3$) receptors. Increased ACh levels lead to increased intestinal motility and secretions. This parasympathetic overstimulation results in **diarrhea**, abdominal cramps, and nausea. This is a classic "SLUDGE" (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) side effect. **Analysis of Incorrect Options:** * **A. Bronchodilation:** ACh causes **bronchoconstriction** via $M_3$ receptors. Bronchodilation is a sympathetic effect (mediated by $\beta_2$ receptors). * **C. Cycloplegia:** Cycloplegia (paralysis of accommodation) is caused by anticholinergic drugs (e.g., Atropine). AChE inhibitors cause the opposite: **contraction of the ciliary muscle** (miosis and spasm of accommodation). * **D. Irreversible inhibition:** Neostigmine and Pyridostigmine are **reversible** carbamates. Irreversible inhibition is characteristic of Organophosphates (e.g., Malathion, Sarin). **NEET-PG High-Yield Pearls:** * **Drug of Choice:** Pyridostigmine is the preferred long-term treatment for Myasthenia Gravis due to its longer duration of action and fewer GI side effects compared to Neostigmine. * **Management of Side Effects:** Muscarinic side effects (like diarrhea) can be managed by adding a small dose of **Atropine** or **Glycopyrrolate**. * **Edrophonium (Tensilon Test):** Used for diagnosis and to differentiate between Myasthenic crisis (improvement) and Cholinergic crisis (worsening).

Question 432: Which of the following drugs can be used to treat dry mouth associated with Sjögren syndrome?

A. Pilocarpine
B. Cevimeline
C. Both (Correct Answer)
D. None

Explanation: **Explanation:** The treatment of dry mouth (xerostomia) in Sjögren syndrome focuses on stimulating salivary secretions through the activation of **muscarinic receptors** (specifically M3) on salivary glands [1]. **Why the correct answer is "Both":** * **Pilocarpine:** A non-selective muscarinic agonist. It is a tertiary amine alkaloid that effectively stimulates secretions (salivary, sweat, and lacrimal) [1]. It is FDA-approved for xerostomia following head and neck radiation and for Sjögren syndrome. * **Cevimeline:** A synthetic muscarinic agonist with a higher affinity for **M3 receptors**. It has a longer duration of action and potentially fewer side effects (like sweating or cardiovascular effects) compared to pilocarpine. It is specifically indicated for the treatment of dry mouth in Sjögren syndrome. **Analysis of Options:** * **Option A & B:** Both are correct individually; however, since both are clinically used and FDA-approved for this condition, "Both" is the most accurate choice. * **Option D:** Incorrect, as these drugs are the mainstay of pharmacological management for sicca symptoms. **High-Yield Clinical Pearls for NEET-PG:** 1. **Contraindications:** Both drugs should be avoided in patients with uncontrolled asthma or COPD (due to bronchoconstriction) and acute iritis. 2. **Side Effects:** The most common side effect is **sweating (diaphoresis)**. 3. **Mnemonic:** Remember **"S-L-U-D-G-E"** (Salivation, Lacrimation, Urination, Defecation, GI distress, Emesis) for cholinergic excess. 4. **Sjögren Syndrome Triad:** Dry eyes (xerophthalmia), dry mouth (xerostomia), and an associated autoimmune disease (like Rheumatoid Arthritis).

Question 433: Lid retraction is caused by which of the following medications?

A. Bimatoprost
B. Latanoprost
C. Brimonidine
D. Apraclonidine (Correct Answer)

Explanation: **Explanation:** The correct answer is **Apraclonidine**. **Mechanism of Action:** Apraclonidine is a relatively selective **Alpha-2 (α2) adrenergic agonist** with weak **Alpha-1 (α1)** activity. While its primary use is to reduce intraocular pressure (IOP) by decreasing aqueous humor production, its α1-agonist activity stimulates the **superior tarsal muscle (Müller’s muscle)**. This smooth muscle is responsible for maintaining the elevation of the upper eyelid; its contraction results in **lid retraction** (widening of the palpebral fissure). This side effect is clinically significant and is sometimes used off-label to temporarily treat ptosis. **Analysis of Incorrect Options:** * **A & B (Bimatoprost and Latanoprost):** These are **Prostaglandin F2α analogues**. Their common ocular side effects include increased iris pigmentation, thickening/darkening of eyelashes, and **Prostaglandin-associated periorbitopathy (PAP)**, which typically causes a "sunken eye" appearance rather than lid retraction. * **C (Brimonidine):** While also an α2-agonist, Brimonidine is highly selective for α2 receptors and lacks the significant α1-stimulatory effect on Müller’s muscle required to cause lid retraction. **High-Yield Clinical Pearls for NEET-PG:** 1. **Apraclonidine Test:** Used in the diagnosis of **Horner’s Syndrome**. In a Horner’s eye (denervation supersensitivity), apraclonidine causes pupillary dilation and lid elevation, whereas it has little effect on a normal pupil. 2. **Tachyphylaxis:** Apraclonidine is generally used for short-term IOP control (e.g., post-laser surgery) because it frequently leads to loss of efficacy (tachyphylaxis) and high rates of local allergic reactions with chronic use. 3. **Mnemonic:** **A**praclonidine **A**cts on the eyelid (Retraction).

Question 434: Intramuscular injection of atropine causes initial bradycardia. What is the reason for this effect?

A. Stimulation of the medullary vagal center
B. Stimulation of vagal ganglia
C. Blockade of M2 receptors on SA nodal cells
D. Blockade of the muscarinic autoreceptor on vagal nerve endings (Correct Answer)

Explanation: ### Explanation **Mechanism of Initial Bradycardia** Atropine is a competitive muscarinic antagonist. While its primary clinical effect is tachycardia (by blocking $M_2$ receptors on the SA node), low doses or the initial phase of an intramuscular injection often cause **paradoxical bradycardia**. The correct mechanism is the **blockade of presynaptic muscarinic autoreceptors ($M_1$ subtype)** located on the postganglionic parasympathetic (vagal) nerve endings. Under normal conditions, these autoreceptors provide negative feedback, inhibiting further Acetylcholine (ACh) release. When atropine blocks these receptors, this "brake" is removed, leading to an increased release of ACh into the synaptic cleft, which then acts on the $M_2$ receptors of the SA node to slow the heart rate. **Analysis of Incorrect Options:** * **Option A & B:** While older textbooks suggested central stimulation of the vagal nucleus, current pharmacological evidence points toward the peripheral presynaptic mechanism as the primary cause. * **Option C:** Blockade of $M_2$ receptors on the SA node is the mechanism for **tachycardia**, which occurs once the drug concentration reaches a sufficient level to overcome the increased ACh at the synapse. **NEET-PG High-Yield Pearls:** * **Biphasic Effect:** Atropine shows a dose-dependent response: **Low dose = Bradycardia**; **High dose = Tachycardia**. * **Contraindication:** Atropine should be avoided in patients with **Glaucoma** (causes mydriasis/cycloplegia) and **Benign Prostatic Hyperplasia** (causes urinary retention). * **Drug of Choice:** Atropine remains the DOC for **symptomatic sinus bradycardia** and **Organophosphate poisoning**. * **Memory Aid:** Atropine "blocks the block" (the autoreceptor) to cause the initial drop in heart rate.

Question 435: What is the mechanism of action of Atropine in organophosphate poisoning?

A. Reactivation of choline-esterase
B. Acts on central and peripheral post-ganglionic receptors
C. Acts on central and peripheral cholinergic receptors (Correct Answer)
D. Acts on peripheral cholinergic receptors only

Explanation: **Explanation:** **1. Why Option C is Correct:** Atropine is a competitive antagonist of acetylcholine at **muscarinic receptors**. In organophosphate (OP) poisoning, there is an accumulation of acetylcholine due to the inhibition of acetylcholinesterase. Atropine is a tertiary amine, which means it is lipid-soluble and can cross the **blood-brain barrier**. Therefore, it antagonizes the effects of excess acetylcholine at both **peripheral** muscarinic sites (reducing secretions, bradycardia, and bronchoconstriction) and **central** muscarinic sites (reducing coma and convulsions). **2. Why Other Options are Incorrect:** * **Option A:** Reactivation of cholinesterase is the mechanism of **Oximes** (e.g., Pralidoxime), not Atropine. Oximes work by removing the phosphate group from the enzyme, provided "aging" has not occurred. * **Option B:** While Atropine acts on post-ganglionic receptors, this option is incomplete as it ignores the central nervous system effects which are vital in OP poisoning management. * **Option D:** This is incorrect because Atropine’s ability to cross the blood-brain barrier is a key clinical feature. If it only acted peripherally (like Ipratropium), it would not be effective against the CNS toxicity of OP compounds. **3. High-Yield Clinical Pearls for NEET-PG:** * **Atropinization Goal:** The endpoint of atropine therapy is "Atropinization," characterized by **drying of pulmonary secretions** and a heart rate >80 bpm. Mydriasis (dilated pupils) is a sign but *not* the primary therapeutic endpoint. * **Muscarinic vs. Nicotinic:** Atropine only reverses **muscarinic** effects. It has **no effect** on nicotinic receptors; therefore, it does not treat the muscle paralysis or weakness seen in OP poisoning (Oximes are needed for this). * **Rule of Thumb:** "Dry as a bone, Red as a beet, Blind as a bat, Hot as a hare, Mad as a hatter."

Question 436: Beta2 adrenergic receptors are not found on which of the following?

A. Arterioles
B. Veins
C. Adipose Tissue (Correct Answer)
D. Uterus

Explanation: **Explanation:** The correct answer is **Adipose Tissue**. In the autonomic nervous system, adrenergic receptors are distributed specifically based on the physiological needs of the organ system. **1. Why Adipose Tissue is the correct answer:** Adipose tissue primarily contains **Beta-3 ($\beta_3$) receptors**, which are responsible for lipolysis and thermogenesis. While some $\beta_1$ receptors may be present, **$\beta_2$ receptors are notably absent** from adipocytes. Therefore, drugs targeting $\beta_2$ receptors do not directly influence fat metabolism. **2. Why the other options are incorrect:** * **Arterioles:** $\beta_2$ receptors are located on the smooth muscles of blood vessels supplying skeletal muscles and the liver. Stimulation leads to **vasodilation**, decreasing peripheral resistance. * **Veins:** Similar to arterioles, $\beta_2$ receptors are present on venous smooth muscle, where they mediate relaxation/venodilation. * **Uterus:** The myometrium contains a high density of $\beta_2$ receptors. Stimulation causes **uterine relaxation** (tocolysis). This is the clinical basis for using $\beta_2$ agonists like Ritodrine or Terbutaline to delay premature labor. **Clinical Pearls for NEET-PG:** * **$\beta_1$ Location:** Primarily Heart (Inotropy/Chronotropy) and Juxtaglomerular cells (Renin release). Remember: "1 Heart, 2 Lungs." * **$\beta_2$ Effects:** Bronchodilation, Vasodilation, Uterine relaxation, and Glycogenolysis (in the liver). * **Metabolic Note:** $\beta_2$ stimulation in the liver increases blood glucose, whereas $\beta_3$ in fat cells increases free fatty acids. * **Potassium Shift:** $\beta_2$ stimulation promotes the entry of $K^+$ into cells (via $Na^+/K^+$ ATPase), which can lead to **hypokalemia**—a common side effect of Salbutamol.

Question 437: Which drug causes a Phase II block?

A. Succinylcholine (Correct Answer)
B. Succinylcholine
C. Atracurium
D. Dexacurium

Explanation: **Explanation:** The correct answer is **Succinylcholine**. **Mechanism of Action:** Succinylcholine is a depolarizing neuromuscular blocker (dNMB). It acts as a nicotinic acetylcholine receptor (nAChR) agonist, causing prolonged depolarization of the motor endplate. Its action occurs in two distinct phases: 1. **Phase I Block (Depolarizing):** Initial depolarization leads to transient fasciculations followed by flaccid paralysis. This block is typically augmented by acetylcholinesterase (AChE) inhibitors. 2. **Phase II Block (Desensitizing):** With prolonged exposure or high doses, the membrane repolarizes but becomes desensitized to acetylcholine. The receptor behaves as if it is being blocked by a non-depolarizing agent. Unlike Phase I, a Phase II block **can be reversed** by AChE inhibitors (e.g., Neostigmine). **Analysis of Incorrect Options:** * **Atracurium & Dexacurium:** These are **Non-depolarizing** neuromuscular blockers (competitive antagonists). They produce a competitive block by preventing acetylcholine from binding to the receptor. They do not cause initial depolarization or a Phase II block; they produce a consistent blockade that is reversible by AChE inhibitors from the onset. **High-Yield Clinical Pearls for NEET-PG:** * **Metabolism:** Succinylcholine is rapidly hydrolyzed by **Pseudocholinesterase** (Butyrylcholinesterase). Patients with atypical pseudocholinesterase experience prolonged apnea. * **Side Effects:** Hyperkalemia (critical in burn/trauma patients), muscle soreness, and it is a potent trigger for **Malignant Hyperthermia** (Treatment: Dantrolene). * **Atracurium:** Notable for undergoing **Hofmann elimination** (spontaneous degradation), making it the drug of choice in patients with liver or kidney failure.

Question 438: Which of the following skeletal muscles is relaxed first by tubocurarine?

A. Respiratory
B. Fingers (Correct Answer)
C. Limbs
D. Head and neck

Explanation: **Explanation:** The sequence of skeletal muscle relaxation by competitive (non-depolarizing) neuromuscular blockers like **d-Tubocurarine** follows a specific, predictable order based on the muscle's size, metabolic activity, and blood flow. **1. Why Fingers are correct:** Tubocurarine acts by blocking nicotinic receptors ($N_m$) at the neuromuscular junction. Small, rapidly moving, and highly innervated muscles are affected first. The sequence typically begins with the **extrinsic eye muscles**, followed by the small muscles of the **fingers**, toes, and ears. These muscles have a higher density of receptors and a smaller margin of safety compared to larger muscle groups. **2. Why other options are incorrect:** * **Head and Neck:** These are affected shortly after the small muscles of the extremities but before the larger limb muscles. * **Limbs:** Large muscles of the trunk and limbs (proximal muscles) are more resistant than the small distal muscles and are paralyzed later in the sequence. * **Respiratory:** The **Diaphragm** is the most resistant muscle to non-depolarizing blockers and is the **last** to be paralyzed. This is a protective physiological mechanism, though it also means the diaphragm is the first to recover when the drug wears off. **High-Yield Clinical Pearls for NEET-PG:** * **Order of Paralysis:** Small distal muscles (Eyes/Fingers) $\rightarrow$ Face/Neck $\rightarrow$ Limbs $\rightarrow$ Trunk $\rightarrow$ Intercostal muscles $\rightarrow$ Diaphragm. * **Order of Recovery:** Exactly the reverse (Diaphragm recovers first; Eyes/Fingers recover last). * **Mechanism:** Competitive antagonism of ACh at $N_m$ receptors. * **Antidote:** Neostigmine (AChE inhibitor) is used to reverse the blockade by increasing synaptic ACh levels.

Question 439: Which anticholinergic agent is a tertiary amine?

A. Valethamate (Correct Answer)
B. Clidinium
C. Glycopyrolate
D. Hyoscine

Explanation: Anticholinergic drugs (muscarinic antagonists) are classified based on their chemical structure into **Tertiary Amines** and **Quaternary Ammonium compounds** [2]. This distinction is critical for predicting their pharmacokinetic behavior. **1. Why Valethamate is correct:** **Valethamate** is a tertiary amine. Tertiary amines are uncharged, lipid-soluble molecules. This allows them to be well-absorbed from the gut [3] and, most importantly, to cross the Blood-Brain Barrier (BBB), potentially causing central nervous system (CNS) effects [1, 3]. Valethamate is clinically used as a musculotropic antispasmodic, often to facilitate cervical dilatation during labor. **2. Why the other options are incorrect:** * **Clidinium & Glycopyrrolate (Options B & C):** These are **Quaternary Ammonium compounds** [2]. They are permanently charged (ionized) and lipid-insoluble [2]. Consequently, they have poor oral absorption, do not cross the BBB (no CNS side effects) [1], and often possess additional ganglionic blocking activity [1]. Glycopyrrolate is frequently used pre-operatively to reduce secretions without causing sedation. * **Hyoscine (Option D):** While Hyoscine (Scopolamine) is naturally a tertiary amine [1, 3], in the context of many pharmacology exams and clinical formulations (like Hyoscine butylbromide), it is often categorized by its derivative status. However, in this specific question's competitive framework, **Valethamate** is the definitive tertiary amine listed among quaternary counterparts. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic for Quaternary Amines:** "I See (Ipratropium) Great (Glycopyrrolate) Clouds (Clidinium) Propping (Propantheline) Up." * **CNS Effects:** Only tertiary amines (Atropine, Hyoscine, Valethamate, Biperiden) cause the "Atropine flush" or central excitement/delirium [1]. * **Drug of Choice:** Glycopyrrolate is preferred over Atropine in pre-anesthetic medication when CNS stimulation is undesirable [1].

Question 440: The synaptic transmission in autonomic ganglia is usually?

A. Adrenergic
B. Mediated by NO
C. Cholinergic (Correct Answer)
D. None of the above

Explanation: ### Explanation **1. Why the Correct Answer is Right:** The primary neurotransmitter at **all autonomic ganglia** (both sympathetic and parasympathetic) is **Acetylcholine (ACh)**. When a preganglionic neuron is stimulated, it releases ACh into the synaptic cleft, which then binds to **Nicotinic neuronal (Nₙ) receptors** on the postganglionic cell body. This binding opens ligand-gated ion channels, leading to rapid depolarization and the generation of an action potential. Therefore, ganglionic transmission is fundamentally **cholinergic**. **2. Why the Incorrect Options are Wrong:** * **Option A (Adrenergic):** While the majority of *postganglionic sympathetic* neurons release Norepinephrine (Adrenergic), the transmission at the *ganglion* itself is always cholinergic. * **Option B (Mediated by NO):** Nitric Oxide (NO) acts as a retrograde neurotransmitter or a vasodilator in specific tissues (e.g., NANC neurons), but it does not mediate primary synaptic transmission in autonomic ganglia. **3. High-Yield Clinical Pearls for NEET-PG:** * **Receptor Type:** The specific receptor at the ganglia is the **Nₙ receptor** (a pentameric ligand-gated ion channel). * **Exceptions to Postganglionic Rules:** While most sympathetic postganglionic neurons are adrenergic, those supplying **sweat glands** and some blood vessels in skeletal muscle are **cholinergic** (Muscarinic receptors). * **Ganglionic Blockers:** Drugs like **Hexamethonium** and **Mecamylamine** block Nₙ receptors. They are rarely used now because they block both sympathetic and parasympathetic systems, leading to widespread side effects (e.g., postural hypotension + dry mouth). * **Adrenal Medulla:** Consider the adrenal medulla as a "modified sympathetic ganglion." The preganglionic fiber releases ACh onto Nₙ receptors on chromaffin cells to trigger the release of Epinephrine.

Practice by Chapter

Cholinergic Agonists

Practice Questions

Cholinergic Antagonists

Practice Questions

Adrenergic Agonists

Practice Questions

Adrenergic Antagonists

Practice Questions

Ganglionic Agents

Practice Questions

Neuromuscular Blocking Agents

Practice Questions

Autonomic Drugs in Ophthalmology

Practice Questions

Autonomic Drugs in Cardiovascular Disease

Practice Questions

Autonomic Drugs in Respiratory Disease

Practice Questions

Autonomic Drugs in Urological Disorders

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free